CSChisa Shukunami

Chisa Shukunami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chisa Shukunami has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Yuji Hiraki

    Department of Cellular Differentiation, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan

    7 shared publications
  • Aki Takimoto

    Department of Cellular Differentiation, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan

    4 shared publications
  • Yuki Sugimoto

    Department of Cellular Differentiation, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan

    2 shared publications
  • Yusuke Oshima

    Department of Cellular Differentiation, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan

    2 shared publications
  • Fumi Tashiro

    Department of Nutrition and Physiological Chemistry, Osaka University Medical School, Suita 565-0871, Japan

    1 shared publication
  • Gerd Scherer

    Institute of Human Genetics, Faculty of Medicine, University of Freiburg, D-79104 Freiburg, Germany

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Scx+/Sox9+ progenitors contribute to the establishment of the junction between cartilage and tendon/ligament

    by Yuki Sugimoto, Aki Takimoto, Haruhiko Akiyama, Ralf Kist, Gerd Scherer, Takashi Nakamura, Yuji Hiraki, Chisa Shukunami

    SRY-box containing gene 9 (Sox9) and scleraxis (Scx) regulate cartilage and tendon formation, respectively. Here we report that murine Scx+/Sox9+ progenitors differentiate into chondrocytes and tenocytes/ligamentocytes to form the junction between cartilage and tendon/ligament. Sox9 lineage tracing in the Scx+ domain revealed that Scx+ progenitors can be subdivided into two distinct populations with regard to their Sox9 expression history: Scx+/Sox9+ and Scx+/Sox9− progenitors. Tenocytes are derived from Scx+/Sox9+ and Scx+/Sox9− progenitors. The closer the tendon is to the cartilaginous primordium, the more tenocytes arise from Scx+/Sox9+ progenitors. Ligamentocytes as well as the annulus fibrosus cells of the intervertebral discs are descendants of Scx+/Sox9+ progenitors. Conditional inactivation of Sox9 in Scx+/Sox9+ cells causes defective formation in the attachment sites of tendons/ligaments into the cartilage, and in the annulus fibrosus of the intervertebral discs. Thus, the Scx+/Sox9+ progenitor pool is a unique multipotent cell population that gives rise to tenocytes, ligamentocytes and chondrocytes for the establishment of the chondro-tendinous/ligamentous junction.


  • Generation and characterization of ScxCre transgenic mice

    by Yuki Sugimoto, Aki Takimoto, Yuji Hiraki, Chisa Shukunami

    Scleraxis (Scx) is a basic helix‐loop‐helix transcription factor that is a marker for the tendon/ligament cell lineage. The ∼11 kb genomic region from the mouse Scx gene locus faithfully recapitulates the endogenous Scx expression pattern in ScxGFP transgenic (Tg) mice. We have established two Tg mouse lines expressing Cre‐recombinase (Cre) using this regulatory region (ScxCre‐L and ScxCre‐H). The specificity and efficiency of Cre recombination in these Tg lines are evaluated by crossing with Rosa‐CAG‐LSL‐tdTomato (Ai14) or ROSA26R (R26R) reporter mice. The recombination in ScxCre‐H;Ai14 mice is efficiently achieved in the endogenous Scx expression domains including the branchial arches, the syndetome, and the lateral plate mesoderm. Further analysis of ScxCre‐H;Ai14;ScxGFP embryos reveal that expression of the ScxGFP transgene largely overlaps with Cre activity detected by tdTomato at embryonic day 12.5 (E12.5). In ScxCre-L;R26R or ScxCre-H;R26R neonates, Cre activity is detected in tendons, ligaments, intervertebral discs, joints, and cartilage around the chondro‐tendinous/ligamentous junction, the prospective enthesis. The present results suggest that ScxCre Tg lines are useful for targeting the gene specifically in the Scx‐expressing domains. genesis 51:275–283.


  • Open Access

    Localization of chondromodulin-I at the feto-maternal interface and its inhibitory actions on trophoblast invasion in vitro

    by Shigenori Miura, Chisa Shukunami, Kaori Mitsui, Jun Kondo, Yuji Hiraki

    Chondromodulin-I (ChM-I) is an anti-angiogenic glycoprotein that is specifically localized at the extracellular matrix of the avascular mesenchyme including cartilage and cardiac valves. In this study, we characterized the expression pattern of ChM-I during early pregnancy in mice in vivo and its effect on invasion of trophoblastic cells into Matrigel in vitro.


  • Chondromodulin-I and tenomodulin are differentially expressed in the avascular mesenchyme during mouse and chick development

    by Chisa Shukunami, Aki Takimoto, Shigenori Miura, Yuriko Nishizaki, Yuji Hiraki

    Chondromodulin-I (ChM-I) and tenomodulin (TeM) are homologous angiogenesis inhibitors. We have analyzed the spatial relationships between capillary networks and the localization of these molecules during mouse and chick development. ChM-I and TeM proteins have been localized to the PECAM-1-negative avascular region: ChM-I is expressed in the avascular cartilage, whereas TeM is detectable in dense connective tissues, including tendons and ligaments. We have also examined the vasculature of chick embryos by injection with India ink and have performed in situ hybridization of the ChM-I and TeM genes. The onset of ChM-I expression is associated with chondrogenesis during mouse embryonic development. ChM-I expression is also detectable in precartilaginous or noncartilaginous avascular mesenchyme in chick embryos, including the somite, sclerotome, and heart. Hence, the expression domains of ChM-I and TeM during vertebrate development incorporate the typical avascular regions of the mesenchymal tissues.


  • Open Access

    Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I

    by Yusuke Oshima, Koji Sato, Fumi Tashiro, Jun-Ichi Miyazaki, Koji Nishida, Yuji Hiraki, Yasuo Tano, Chisa Shukunami

    Tenomodulin (TeM) is a type II transmembrane glycoprotein that contains a C-terminal domain with homology to the mature, secreted form of chondromodulin-I (ChM-I), a cartilage-derived angiogenesis inhibitor. TeM transcripts have been found in hypovascular tissues such as tendons and ligaments but the biological activity of TeM has not yet been fully explored. Using an adenovirus expression system, we utilized the forced expression and subsequent secretion of the human TeM C-terminal 116 amino acids (Ad-shTeM) in human umbilical vein endothelial cells (HUVECs) to assess the anti-angiogenic properties of TeM. The C-terminal 120 amino acids of the human ChM-I precursor (Ad-shChM-I) was similarly expressed in HUVECs as a comparison study. Transduction of both Ad-shTeM and Ad-shChM-I resulted in significant impairment of the tube-forming activity of HUVECs, when cultured in Matrigel. Similarly, conditioned medium from COS7 cells, transfected with plasmid DNA encoding shTeM or shChM-I, inhibited tube formation of HUVECs when compared to medium derived from either COS7 cells transfected with control vector or from non-transfected cells. Upon infection of HUVECs with Ad-shTeM or Ad-shChM-I, DNA synthesis stimulated by vascular endothelial growth factor (VEGF) was reduced to 40-50% of normal levels. Additionally, in a modified Boyden chamber assay, migration of HUVECs in response to VEGF was significantly affected following transduction of either Ad-shTeM or Ad-shChM-I and these transduced HUVECs were found to spread well on type I collagen or fibronectin, but not on vitronectin. Furthermore, the transduction of either Ad-shTeM or Ad-shChM-I in human melanoma cells resulted in suppression of tumor growth in association with decreased vessel density in vivo. Hence, we have demonstrated that, similarly to ChM-1, the C-terminal domain of TeM exhibits both anti-angiogenic and anti-tumor activities when expressed in a secreted form.


    • 1 September 2000
      • Vol. 45, 2131-8

    [Angiogenic inducers and inhibitors].

    by C Shukunami, Y Hiraki

  • Generation of multiple transcripts from the chicken chondromodulin‐I gene and their expression during embryonic development

    by Chisa Shukunami, Saori Yamamoto, Tadashi Tanabe, Yuji Hiraki

    Chondromodulin‐I (ChM‐I) is an angiogenesis inhibitor isolated from fetal bovine cartilage. Here, we report the nucleotide sequence of chicken ChM‐I cDNA. Chicken mature ChM‐I had a significantly larger N‐terminal hydrophilic domain than its mammalian counterparts. Chicken embryos expressed multiple transcripts (3.3, 2.0 and 1.7 kb in size) due to the alternative utilization of polyadenylation signals, whereas only the 1.7 kb transcripts were detected in mammals. Although confined to cartilage and eye at a later stage of development, whole‐mount in situ hybridization revealed the expression of ChM‐I mRNA in somites, heart, bronchial arches, roof plate, retina and limb buds. The expression pattern of the gene suggests a role for ChM‐I in the morphogenesis during embryonic development.